22 COVID-19 vaccines enter clinical trials in China: health official
Xinhua |
Updated: 2021-07-08 19:36
Share
Share - WeChat
BEIJING - Twenty-two COVID-19 vaccines have been approved to enter clinical trials in China, a health official said Thursday.
To date, four COVID-19 vaccines have been granted conditional marketing approval and three have been authorized for emergency use within the country, said Yuan Lin, an official with the National Medical Products Administration (NMPA), at a press conference in Beijing.
By the end of June, the NMPA had granted emergency approval for clinical trials to 25 drugs intended for the treatment of COVID-19 and its indications, Yuan added.
- Chang'e 6 samples show moon's asymmetry
- Vice-premier calls for more efficient policy implementation
- Top political adviser urges sustained pairing assistance to Xinjiang
- Top legislator stresses high-quality legislative work
- Global representatives hail Shanghai's achievements
- National health body bans use of LVA surgery to treat Alzheimer's
